OTC · CIK 0001415397
RAPH Raphael Pharmaceutical Inc.
Insider trading from SEC Form 4. Last filing Apr 6, 2026.
In brief
Raphael Pharmaceutical Inc. (RAPH) has 3 SEC Form 4 filings on file from 3 insiders, the latest filed on Apr 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Raphael Pharmaceutical Inc., scored.
Transactions
Every row filed, 6 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | Hayon Igal Louria Chief Technology Officer | XIn-the-money exercise Common Stock | +350,000 | $0.01 | $3,500 | 1,349,000 | Apr 6, 2026 |
| Nov 20, 2025 | Hayon Igal Louria Chief Technology Officer | XIn-the-money exercise Warrants to purchase Common Stockderivative | -350,000 | - | - | 0 | Apr 6, 2026 |
| Mar 10, 2025 | Yehuda Eliya director | AGrant or award Warrant to purchase Common Stockderivative | +200,000 | $0.00 | $0 | 200,000 | Mar 12, 2025 |
| May 12, 2022 | Yehuda Eliya director | EExpiration of short derivative Warrant to purchase Common Stockderivative | -202,000 | $0.00 | $0 | 0 | Mar 12, 2025 |
| Mar 5, 2025 | Ajay Kumar Dhadha director | AGrant or award Common Stock | +350,000 | $0.00 | $0 | 351,667 | Mar 6, 2025 |
| Mar 5, 2025 | Ajay Kumar Dhadha director | AGrant or award Warrant to purchase Common Stockderivative | +250,000 | $0.00 | $0 | 250,000 | Mar 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Ajay Kumar Dhadhadirector
- Yehuda Eliyadirector
- Hayon Igal LouriaChief Technology Officer
Questions about RAPH
Answered from the filings on this page, as of the latest one.
Are insiders buying RAPH?
No. In the last 90 days no insider at Raphael Pharmaceutical Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RAPH on the open market?
No open-market trade has been scored at Raphael Pharmaceutical Inc.. The latest Form 4 on file was filed on Apr 6, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Raphael Pharmaceutical Inc.?
3 people have filed a Form 4 at Raphael Pharmaceutical Inc., among them Ajay Kumar Dhadha (director), Yehuda Eliya (director), Hayon Igal Louria (Chief Technology Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.